Cite
[Clinical observation of palbociclib combined with endocrine therapy in hormone receptor positive and HER2 negative advanced breast cancer].
MLA
Lyu, H. M., et al. “[Clinical Observation of Palbociclib Combined with Endocrine Therapy in Hormone Receptor Positive and HER2 Negative Advanced Breast Cancer].” Zhonghua Yi Xue Za Zhi, vol. 101, no. 44, Nov. 2021, pp. 3625–30. EBSCOhost, https://doi.org/10.3760/cma.j.cn112137-20210416-00912.
APA
Lyu, H. M., Niu, L. M., Zhang, M. W., Zeng, H. A., Zhao, S. N., Liu, Z. Z., & Yan, M. (2021). [Clinical observation of palbociclib combined with endocrine therapy in hormone receptor positive and HER2 negative advanced breast cancer]. Zhonghua Yi Xue Za Zhi, 101(44), 3625–3630. https://doi.org/10.3760/cma.j.cn112137-20210416-00912
Chicago
Lyu, H M, L M Niu, M W Zhang, H A Zeng, S N Zhao, Z Z Liu, and M Yan. 2021. “[Clinical Observation of Palbociclib Combined with Endocrine Therapy in Hormone Receptor Positive and HER2 Negative Advanced Breast Cancer].” Zhonghua Yi Xue Za Zhi 101 (44): 3625–30. doi:10.3760/cma.j.cn112137-20210416-00912.